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ABSTRACT
Protein p56 encoded by the Bacillus subtilis phage
r29 inhibits the host uracil-DNA glycosylase (UDG)
activity. To get insights into the structural basis for
this inhibition, the NMR solution structure of p56 has
been determined. The inhibitor defines a novel
dimeric fold, stabilized by a combination of polar
and extensive hydrophobic interactions. Each poly-
peptide chain contains three stretches of
anti-parallel b-sheets and a helical region linked by
three short loops. In addition, microcalorimetry ti-
tration experiments showed that it forms a tight
2:1 complex with UDG, strongly suggesting that
the dimer represents the functional form of the in-
hibitor. This was further confirmed by the functional
analysis of p56 mutants unable to assemble into
dimers. We have also shown that the highly
anionic region of the inhibitor plays a significant
role in the inhibition of UDG. Thus, based on these
findings and taking into account previous results
that revealed similarities between the association
mode of p56 and the phage PBS-1/PBS-2-encoded
inhibitor Ugi with UDG, we propose that protein p56
might inhibit the enzyme by mimicking its DNA
substrate.
INTRODUCTION
Damage to DNA arises continually throughout the cell
cycle and must be recognized and repaired prior to the
next round of replication to maintain the genomic integ-
rity of the cell. Uracil is one of the most common lesions in
DNA (1,2). If left unrepaired, this change may impair
protein–DNA interactions (3) or can induce G:C to A:T
transition mutations during subsequent rounds of DNA
replication (4). Uracil-DNA glycosylase (UDG) speciﬁcal-
ly recognizes uracil in DNA and initiates the base-excision
repair (BER) mechanism by hydrolysing the N–C1
0
glyco-
sidic bond linking the uracil to the deoxyribose. This
creates an abasic site that is removed by a 50-acting
apurinic/apyrimidinic (AP) endonuclease, leaving a gap
that is ﬁlled by DNA polymerase and closed by DNA
ligase. Four distinct families of UDGs have been identiﬁed
in most prokaryotic and eukaryotic cells, showing very
limited sequence similarity to each other, although
family-1, the most ubiquitous, and family-2 proteins have
been reported to possess the same structural fold (5,6). In
addition, some DNA viruses, such as herpesviruses and
poxviruses, also encode a UDG activity, whereas the
human immunodeﬁciency virus type 1 packages cellular
UDG (UNG2 enzyme) into virus particles. In these
cases, the UDG activity appears to have an important
role in virus replication (7,8).
Bacteria in their natural environment are faced with
predation by both macro- and microorganisms. Some of
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phages. They have evolved different means of adapting
to their host cells. For instance, it is known that several
phages synthesize unique proteins that block critical
cellular processes. These include proteins able to inhibit
uracil-DNA repair of the host bacteria. The phage PBS-1/
PBS-2 inhibitor Ugi represents the ﬁrst example of such
proteins (9–17). Ugi inactivates UDG by forming an irre-
versible 1:1 complex with the enzyme. The structural bases
for this inhibitory activity have been analysed employing
both NMR and X-ray methods. According to these data,
complex formation is accompanied by a remarkable con-
formational change in the inhibitor, leading to a signiﬁ-
cant shape and electrostatic complementarity between
interacting surfaces. Interestingly, the particular contacts
observed at the UDG–Ugi interface suggest that Ugi
achieves its tight binding by acting as a DNA mimic
(12,16,17).
Recently, we reported the identiﬁcation of a novel low
molecular weight (56 amino acids) acidic inhibitor of the
Bacillus subtilis UDG (18), called p56, which is encoded by
the B. subtilis phage f29. We have proposed that p56
constitutes a defence mechanism to prevent the deleterious
effect caused by UDG due to elimination of uracil residues
that may be present in the f29 genome (19). In recent
years, UDGs have emerged as attractive therapeutic
targets due to their role in a wide range of biological
processes including the generation of antibody diversity,
DNA replication in a number of viruses and the formation
of DNA strand breaks during anti-cancer drug therapy.
Consequently, the identiﬁcation and characterization of
new molecules able to inhibit the activity of particular
UDGs has a great interest. Indeed, some synthetic inhibi-
tors of UDG have been designed to inhibit the human
UNG enzyme (20). Herein, we address the structural
bases for UDG inhibition by protein p56, combining the
NMR structural study of p56 with the functional analysis
of speciﬁc single and multiple mutants of the inhibitor.
MATERIALS AND METHODS
DNA substrates
To test the UDG activity, 34-mer oligonucleotides con-
taining a single uracil (U) residue at position 16
(ssDNA-U16) (obtained from Isogen Bioscience BV)
were used as ssDNA substrate. They were 50-labelled
with [g-
32P] ATP (3000Ci/mmol) (Perkin Elmer Life
Science) and phage T4 polynucleotide kinase (New
England Biolabs), and puriﬁed electrophoretically on
8M urea/20% polyacrylamide gels. To generate dsDNA
substrates, the 50-
32P-labelled oligonucleotides were an-
nealed to complementary non-labelled oligonucleotides
(34-mer), containing either a guanine or adenine residue
opposite to uracil in a buffer containing 20mM Tris–HCl,
pH 8.0 and 60mM NaCl, heating at 70 C for 10min and
then slowly cooling to room temperature.
Construction of the expression plasmids
Gene ung of B. subtilis, which encodes UDG, was cloned
in the Escherichia coli expression vector pGEX-2T
(GST Gene Fusion System, GE Healthcare) and the re-
sulting plasmid pGEX-2T-UDG wt was expressed in
E. coli BL21 cells as described (21). Plasmid pT7-3-p56-
f29, containing the p56-encoding gene of phage f29 was
constructed as described (21).
Site-directed mutagenesis of protein p56
The p56 mutants were obtained by using the QuickChange
site-directed mutagenesis kit obtained from Stratagene.
Vector pT7-3-p56 containing phage f29-p56 gene, was
used as template for the mutagenesis reaction. After
PCR using Pfu turbo DNA polymerase and treatment
with DpnI endonuclease, ampliﬁed DNA was transformed
into E. coli BL21(DE3) competent cells. The presence of
the desired mutations and the absence of non-desired ones
were conﬁrmed by sequencing the entire gene.
Overexpression and puriﬁcation of UDG and p56 proteins
Bacillus subtilis UDG was expressed and puriﬁed as
described (21). Protein p56, wild-type and mutants, were
overproduced in E. coli BL21(DE3) cells harbouring plas-
mids with the corresponding p56 gene and were puriﬁed as
described (21). Puriﬁed proteins were quantiﬁed by gel
densitometry and stored at  70 C.
Determination of UDG activity
UDG activity and the effect of protein p56 on the UDG
activity were determined as described (21).
Sedimentation through glycerol gradients
Samples containing a mixture of lysozyme (15mg),
aprotinine (15mg) and p56 (12mg) proteins were loaded
on top of a continuous 15–30% (v/v) glycerol gradient
(4ml) in the presence of 50mM Tris–HCl, pH 7.5, 0.2M
NaCl, 1mM EDTA and 7mM b-mercaptoethanol, and
centrifuged at 4 C for 49h at 59000rpm in a Beckman
TST 60.4 rotor. Gradients were fractionated and subjected
to SDS–10–20% PAGE. Gels were stained after electro-
phoresis with Coomassie blue.
Isothermal titration microcalorimetry experiments
Binding studies were performed at 25 C in 10mM sodium
phosphate, pH 6.5 and 100mM NaCl using a VP-ITC
titration calorimeter (MicroCal, LLC) with a reaction
cell volume of 1.467ml. Both, enzyme and inhibitor solu-
tions were dialysed against the same buffer prior to
Isotermal Titration Microcalorimetry (ITC) experiments
to ensure chemical equilibration. A solution 13mMo f
UDG in the reaction cell was titrated with a 300mM
solution of p56 (monomer concentration) contained in a
300-ml syringe. At least 30 consecutive injections of 8ml
were applied at 5-min intervals, while the UDG solution
was stirred at a constant speed of 300rpm. Dilution heats
of p56 into UDG solution (which agreed with those
obtained by injections of the protein into the same
volume of buffer) were subtracted from measured heats
of binding. Titration curves were analysed with Origin,
provided with the instrument by MicroCal LLC, using a
one-site binding model to ﬁt the curves. Thermodynamic
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NMR experiments
1H-NMR spectra were recorded in 90:10
1H2O:
2H2Oo n
Bruker Avance 800, Bruker AMX-600 and Varian Unity
500MHz spectrometers. Protein concentrations for the
structural analysis of the protein dimer were in the
400–800mM range in, 10mM sodium phosphate, pH 5.0
and 100mM NaCl. Protein assignments were obtained
using a set of 2D- and 3D homo- and heteronuclear
NMR experiments performed at 35 C on the unlabelled,
15N-labelled and
13C/
15N double-labelled molecules. Thus,
HNCACB and CBCA(CO)NH spectra were employed for
backbone assignment. NOE distance restraints were
obtained from
15N- or
13C-edited 3D-NOESY spectra.
In addition, 2D-NOESY,
13C-selected-
12C-ﬁltered experi-
ments were performed on a heterolabelled dimer to analyse
the interprotein contacts. This protein sample was gene-
rated by mixing equimolar amounts of unlabelled and
13C/
15N double-labelled protein to a global protein con-
centration of 100mM in 10mM phosphate buffer, pH 5.0
and 100mM NaCl. The sample was incubated at 40 C for
24h and then concentrated for NMR analysis.
Upper limits for proton–proton distances were obtained
from NOESY cross-peak intensities at three mixing times,
50, 75 and 150ms. Cross-peaks were classiﬁed as strong,
medium, and weak corresponding to upper limits of 2.6,
3.5 and 5.0A ˚ . The lower limit for proton–proton distances
was set as the sum of the van der Waals radii of the
protons. Structure calculations were performed using the
program DYANA (22). A set of 1380 constraints (120
interprotein) were used in the ﬁnal round of calculations.
The 30 best DYANA structures in terms of target function
were subjected to a simulated annealing protocol with the
AMBER 10.0 package (23,24).
RESULTS AND DISCUSSION
Stoichiometry of the p56–UDG complex determined by
microcalorimetry
By analytical ultracentrifugation, it has been shown that
p56 is dimeric under physiological conditions (25). To de-
termine the stoichiometry of the p56–UDG complex, the
binding of the inhibitor to the enzyme was analysed by
Isothermal Titration Microcalorimetry (ITC). A typical
titration proﬁle together with the Kb, G and H param-
eters derived from titration experiments, assuming a single
set of binding sites in the enzyme, is shown in Figure 1.
According to these data, one p56 dimer binds to a single
UDG molecule to form a 2:1 p56–UDG complex. From a
structural perspective, the observed stoichiometry is
intriguing and strongly suggests that a signiﬁcant
fraction of the surface of the inhibitor dimer must be
occluded by the enzyme upon binding so that the associ-
ation of a second UDG molecule to form a symmetric 2:2
complex is impeded. It should be noted that this implies
that p56 dimerization is probably essential for complex
formation (this was conﬁrmed by the functional analysis
of speciﬁc p56 mutants. See below).
Regarding the stability of the complex, the combination
of very high afﬁnity and low enthalpy prevented an
accurate measurement of Kb, which seems to be in the
10
8M
 1 range. Thus, the unusually low enthalpy value
detected for such tight interaction might point to a
dominant role of electrostatic forces in the stabilization
of the enzyme–inhibitor complex. These data are consist-
ent with our previous ﬁndings showing that the interaction
between UDG and p56 is stable at high urea (6M) con-
centrations (25).
Architecture of the p56 dimer
To gain insights into the mechanism underlying the UDG
inhibition by protein p56, we analysed the solution struc-
ture of the inhibitor by NMR. Backbone and side-chain
assignments (Supplementary Figure S1 and Table S1) of
p56 were obtained using standard 2D and 3D NMR tech-
niques on
15N- and
13C/
15N-labelled samples. In order to
distinguish intra- from intermolecular NOEs, half-ﬁltered
NOESY experiments were carried out on a heterolabelled
dimer formed by mixing equivalent amounts of unlabelled
and
13C/
15N-labelled protein. A summary of the experi-
mental constraints employed and the characterization of
the ﬁnal NMR ensemble is shown in Table 1 (see also
Supplementary Table S2).
The solution structure of the p56 dimer is shown in
Figure 2, together with the electrostatic potential at the
protein surface. In addition, details of the dimerization
inter-phase are presented in Figure 3. According to the
NMR data, each polypeptide chain contains three
stretches of anti-parallel b-sheets ( 1: residues 10–17;  2:
residues 22–29;  3: residues 48–54) and a helical region
( 1: residues 33–43) linked by short loops (L1: residues
18–21; L2: residues 30–32 and L3: residues 44–47). The
Figure 1. Stoichiometry of the p56–UDG interaction as deduced from
isothermal titration calorimetry (ITC). UDG solutions were titrated
with p56 inhibitor at 25 C in 10mM sodium phosphate, pH 6.5 and
100mM NaCl. The experimental curves were ﬁtted assuming a single
set of sites on the enzyme. The obtanied stoichiometry factor (n),
binding constant (Kb), binding free energy (G) and enthalpy (H)
values are shown.
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 3. It can be observed that helix a1 sits on strand b1 with a
parallel orientation, forming a prominent and extensive
hydrophobic core. Numerous NOE contacts connecting
these protein regions were observed in both 2D and 3D
experiments.
While the overall structure appears well deﬁned
(Figure 2A and Table 1), the NMR ensemble exhibits a
signiﬁcant dispersion at four distinct regions of the poly-
peptide: the N-terminal segment (residues 1–7), the
C-terminal end of helix  1 (residues 41–43) and loops
L1/L3 (comprising residues 18–21 and 44–47, respectively).
The lack of structural deﬁnition at the helical segment is
probably related with the presence of a glycine (a residue
with a very low helical propensity) at position 41. Indeed,
the medium-range NOEs at this protein region are con-
sistent with a signiﬁcantly reduced helical content.
In a similar way, diverse experimental evidences (as the
extreme line broadening observed for speciﬁc proton
signals in residues 44 and 47) indicate that, at least for
the N-terminus and loop L3, the lack of structural deﬁn-
ition is caused by substantial local motions of the protein
backbone.
Resolution of the crystal structure of phage PBS-2 in-
hibitor Ugi revealed that this protein is essentially an
anti-parallel b-sheet made up of ﬁve contiguous strands
with a helix in the polypeptide stretch that connects
strands 1 and 2 (16,17). It should be noted that, despite
the existing similarities in secondary structure between p56
and Ugi, both protein inhibitors exhibit a fundamentally
different fold (Figure 2C). Indeed, a DALI (26) search
reveals that p56 deﬁnes a novel dimeric structure, not
having high structural homology with any of the
proteins present in the Brookhaven Protein Data Bank.
It can be observed that the two monomers, related by a
2-fold symmetry axis, are held together by a combination
of hydrogen bonding, and extensive hydrophobic and elec-
trostatic interactions. Two speciﬁc regions of p56 seem to
play a key role in the stabilization of the structure: strand
b3 and the helical segment a1 (Figures 2, 3, Supplementary
Figure S2 and Table S2). In the following description of
the main intermolecular contacts, letters a and b will be
employed as subscript to specify the polypeptide chain
only when essential to avoid ambiguities. Thus, strands
 3 of both monomers ( 3a and  3b) extend across the
dimer interface in a 2-fold symmetric fashion to create a
continuous six-stranded anti-parallel b-sheet. This par-
ticular arrangement implies that the two helices,  1a and
 1b, lye anti-parallel to one another on the same side of the
b-sheet. Residues on strands  3a/ 3b with side chains
pointing to the helical segments  1a/ 1b are mainly ali-
phatic and participate in numerous intermolecular inter-
actions. Most relevant contacts at this region involve pairs
L33a/I47b, L50a/L50b and I47a/L33b (Figure 3B). In
addition, helices  1a/ 1b contribute to the stabilization of
this hydrophobic core through residues L33, F36 and Y40,
which are also involved in numerous intra- and intermo-
lecular packing interactions. Intriguingly, two acidic
amino acids, E37a and E37b, are located at the centre of
the helical segments, pointing to the dimerization inter-
face. It seems unlikely that these residues have a favour-
able inﬂuence on the protein stability, especially
considering the proximity between both charged side-
chains within the dimer structure and the hydrophobic
nature of most of the surrounding positions. Finally, the
water-exposed face of strand  3 is characterized by a sig-
niﬁcant fraction of charged residues. More speciﬁcally,
this region seems to contribute to the stabilization of the
p56 dimer by means of two, symmetry related, bifurcated
salt-bridges involving triads K49a/D53b/R51b and K49b/
D53a/R51a.
Protein p56 dimerization is required for the inhibition of
UDG
The NMR structure of p56 provides a detailed description
of the particular interactions involved in the stabilization
of the protein dimer. This information was used to analyse
the role that p56 dimerization plays on UDG inhibition.
More speciﬁcally, we investigated whether dimer forma-
tion is required to inhibit the UDG activity. To this end,
several residues located at the protein–protein interface of
the inhibitor were substituted by Ala, and the inﬂuence of
the mutations on both the dimer stability and its inhibi-
tory activity were evaluated. The mutated positions
included hydrophobic and polar side-chains located at
both sides of the dimerization interface (formed by
helical segments  1a/ 1b and strands  3a/ 3b). In particu-
lar, single mutants Y40A and D53A, and the double
mutant K49A/R51A were constructed and puriﬁed as
described in ‘Materials and Methods’ section. According
to the NMR structure of p56, Y40 is partially buried in an
extensive hydrophobic core deﬁned by the packing of both
p56 monomers. In contrast, D53, K49 and R51 are
located on the water exposed surface of the six-stranded
Table 1. Characterization of the 20 NMR structures of the p56
dimer retained for structural analysis
NMR distance constraints
Total distance constraints 1380
Intraresidue 216
Sequential 268
Medium and long range 896
Intra-monomer 1260
Inter-monomer 120
RMSD (residues 8–55, 20 structures)
AMBER backbone RMSD (dimer) 1.17±0.24
AMBER heavy atom RMSD (dimer) 1.88±0.21
AMBER backbone RMSD (monomer) 1.02±0.28
AMBER heavy atom RMSD (monomer) 1.77±0.26
RMSD (residues 8–17, 23–43, 46–55, 20 structures)
AMBER backbone RMSD (dimer) 0.82±0.13
AMBER heavy atom RMSD (dimer) 1.60±0.14
AMBER backbone RMSD (monomer) 0.76±0.15
AMBER heavy atom RMSD (monomer) 1.54±0.20
Distance constraints violations (>0.2A ˚ )
Sum of violations 1.41 (1.11–1.69)
Maximum violation 0.17 (0.14–0.21)
AMBER energies (kcal/mol)
Restraint AMBER energy 7.5 (5.4–9.2)
Total AMBER energy  1476 ( 1255 to  1764)
RMSD values and violations are given in angstroms.
9782 Nucleic Acids Research, 2011,Vol.39, No. 22Figure 2. (A) Backbone trace for the 20 lowest energy structures in the ﬁnal NMR ensemble of the p56 dimer (Top) together with a ribbon
representation of a single conformer (Bottom). Different monomeric units are labelled with subscripts a and b. Secondary structure elements are
indicated by colour coding: a-helices (a1, red), b-strands (b1–b3, green), and loops (L1–L3, yellow). The disordered N-terminal tails (residues 1–7) are
omitted for clarity. (B) Molecular surface representations of p56 showing the electrostatic potential (blue is positive and red is negative). The
orientation of the p56 dimer in the top view is identical to that of the NMR ensemble shown in (A). Bottom view is related with the former by a 180 
rotation around the x-axis. The position of the charged residues contributing to the inhibitor electrostatic potential is indicated. (C) Top: ribbon
representation of the UDG-bound form of the inhibitor Ugi from phage PBS-1/PBS-2 (16) (pdb code 1EUI). Bottom: molecular surface represen-
tation showing the electrostatic potential at the UDG-binding surface of Ugi inhibitor.
Figure 3. (A) Double-ﬁltered (left) and half-ﬁltered (right) NOESY experiments acquired for p56 at 35 C (buffer conditions: 100mM NaCl and
10mM sodium phosphate, pH 5.0). Inter-protein NOE contacts involving the aromatic ring of Y40 and residues E37, L33 and L52 are clearly
observable in the half-ﬁltered spectrum (labelled in red). (B) Structural details of p56 dimerization interface. Protein side-chains involved in relevant
protein–protein contacts are highlighted (aromatic, in green; aliphatic, in yellow; positively charged, in cyan; negatively charged, in red). The protein
backbone is shown in grey. Different monomeric units are labelled with subscripts a and b. Top and bottom views are related by a 180
o rotation
around the x-axis. (C) Ensemble of 20 NMR structures showing the inhibitor side-chains involved in dimerization.
Nucleic Acids Research, 2011,Vol.39, No. 22 9783b-sheets formed by the p56 dimer, and participate presum-
ably in stabilizing bifurcated salt-bridges (Figure 3). It is
noteworthy that this particular choice (mutated residues at
buried sites or exposed on the positively charged surface of
the protein) strongly reduces the probability that direct
p56–UDG contacts are removed by the substitutions
leading to a drop in inhibitory activity.
The oligomerization state of p56 mutants was analysed
by glycerol gradient sedimentation. As shown in
Figure 4A, p56 wild-type sedimented in glycerol gradients
near the position of lysozyme, which is in agreement with
its dimeric state. In contrast, peaks corresponding to
Y40A, D53A or K49A/R51A mutants were displaced
towards the top of the gradient, indicating that such
mutants failed to assemble into dimers. This result is
fully consistent with the structural information and
shows that the selected positions play a key role in the
stabilization of the p56 dimer. Then, the ability of the
dimerization mutants to inhibit the UDG activity was
determined. To this end, the 34-mer oligonucleotide con-
taining a single uracil was incubated with 5 pg of UDG in
the presence of different amounts of p56 mutants (from
0.2 to 5.4ng). Interestingly, these experiments revealed a
signiﬁcant drop of the inhibitory activity for all the
mutants (Figure 4B and C). More speciﬁcally, the
capacity of mutants Y40A and D53A to block the UDG
activity was decreased 18- and 14-fold, respectively. The
double mutant was less affected, though it only retained
20% of its inhibition activity. The higher activity exhibited
by the K49A/R51A mutant with respect to the D53A
mutant might reﬂect the increased anionic character of
the former. Overall, the results obtained strongly suggest
that the two monomers of p56 participate in contacts with
UDG. In addition, it should be considered that monomer-
ic p56 would probably exhibit both an enhanced internal
mobility and a reduced stability, which could have a sig-
niﬁcantly unfavourable inﬂuence on its binding properties.
Indeed, p56 solution structure strongly suggests that
folding and dimerization are strongly coupled.
Altogether our data indicate that the formation of p56
dimer is a necessary step for inhibition of UDG.
Effects of mutations in acidic residues on the inhibition
activity of p56
It has been shown that the tight binding of the protein
inhibitor Ugi to human UDG arises from its ability to
functionally mimic substrate DNA (12). In agreement
with this, Ugi regions involved in UDG recognition
exhibit a strongly negative electrostatic potential
(Figure 2C). Recent studies have shown that Ugi, which
interacts with the DNA-binding groove of the enzyme,
replaces the highly acidic protein p56 previously bound
to E. coli UDG, implying that both inhibitors present at
least partially overlapping binding sites on the enzyme
(25). Moreover, it has also been shown that p56
competes with DNA for binding to UDG and that the
formation of UDG–p56 complex blocks the interaction
between the enzyme and DNA (25). Altogether, these
results suggest that, the p56 surface involved in UDG rec-
ognition should be strongly anionic. Interestingly, acidic
amino acids are present at equivalent positions in most
p56-like proteins (21), which might suggest a possible
role for them in UDG inhibition. Furthermore, as
shown here, the NMR solution structure of p56 revealed
that most aspartates and glutamates fall in the same face
of the dimer, speciﬁcally, at the surface deﬁned by helices
a1a/a1b and loop regions L1a/L1b and L3a/L3b (Figure 2B).
Indeed, triads D18a/D19a/D20a and D18b/D19b/D20b,
present in the protruding loops L1a/L1b, together with
pairs D45a/E46a and D45b/E46b, and residues E37a/
E37b, confer to these regions a strongly negative potential.
On the contrary, the opposite side of p56, deﬁned by the
water exposed surface of the six-stranded b-sheet exhibits
a moderate positive potential, which results from the
presence of up to eight basic side-chains of K22a/K22b,
K49a/K49b, R51a/R51b and K54a/R54b. Hence, according
to this analysis, helical regions a1a/a1b and loops L1a/L1b
and L3a/L3b constitute the most likely UDG-binding
surface of p56.
To test this hypothesis, we analysed the role of speciﬁc
p56 acidic residues in the UDG inhibition. In particular,
we focused our attention on glutamate/aspartate
side-chains clustered on particular regions of the inhibitor
and also on those conserved in most p56-like proteins
from other f29-related phages (21). Thus, we constructed
two single mutants at positions 26 and 37, in which
conserved acidic residues were replaced by alanine. In
addition, acidic residues clustered on loop L1 were
neutralized by the triple mutation D18A/D19A/D20A.
These positions, together with E37, contribute consider-
ably to the negative electrostatic potential exhibited by the
proposed p56 UDG-binding surface. Finally, we
generated the triple mutant D5A/D8A/D11A, with substi-
tutions in the N-terminal tail of the protein. It should be
noted that, with the exception of E37, all the residues con-
sidered are water exposed and far from the dimerization
interface. Consequently, it is unlikely that the selected mu-
tations have a signiﬁcant inﬂuence on the protein stability
or structure. As shown in Figure 5A, a strong inhibition of
uracil excision by UDG was observed in the presence of
0.8ng of wild-type p56. For the mutant D18A/D19A/
D20A, a 16-fold increase in the concentration of the in-
hibitor was required to detect the same effect (Figure 5C).
In contrast, the triple mutant D5A/D8A/D11A exhibited
a modest 2-fold decrease in the inhibition activity.
Regarding the substitutions at conserved positions 26
and 37, the mutants were much less efﬁcient than the
wild-type p56 at preventing the cleavage of uracil-
containing substrate by UDG, especially mutant E37A
(Figure 5A and B). More speciﬁcally, E26A and E37A
lost 87% and 96%, respectively, of inhibition activity
with respect to the wild-type protein (Figure 5C).
Therefore, our results conﬁrm the key role played by
acidic residues present in loop L1 and at positions 26
and 37 in UDG inhibition, likely due to the fact that
these amino acids are involved in binding to the UDG.
This is consistent with mutational analysis studies carried
out with protein Ugi, which showed the role of electro-
static interactions between the speciﬁc acidic residues of
the b1 edge of the inhibitor with the active site residues of
E. coli UDG in the formation UDG–Ugi complex (15,17).
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charged residues required for the interaction with UDG,
these inhibitors exhibit a clearly different protein structure
and distinct binding stoichiometries. On the other hand,
the ﬁndings suggest that p56 N-terminal region plays a
modest role in the inhibition, maybe contributing to the
stabilization of the p56–UDG complex by long-range
non-speciﬁc electrostatic interactions. In fact, negative
electrostatic ﬁeld present in proteins that mimic DNA,
such as transcription factor dTAFII230 from Drosophila
and bacteriophage T7 Ocr protein, has been reported to
facilitate productive collisions between such proteins and
their targets (27–29).
CONCLUSION
To gain insights into the UDG inhibition mode by protein
p56, the NMR solution structure of the inhibitor has been
determined. According to these data, p56 deﬁnes a novel
dimeric structure characterized by a 2-fold symmetry axis.
The protein dimer seems to be stabilized by a combination
of polar and extensive hydrophobic interactions involving
mainly residues located on helices a1a/a1b and b-strands
b3a/b3b. The relevance of these positions in p56 dimeriza-
tion has been shown by site-directed mutagenesis.
Furthermore, the functional analysis of speciﬁc mutants
of the protein, unable to assemble into dimers, conﬁrmed
that this process is essential for UDG inhibition, as
deduced from the microcalorimetry assays.
On the other hand, p56 solution structure also revealed
the presence of a large solvent exposed surface
characterized by a strongly negative electrostatic poten-
tial. This comprises the helical segments, together with
loops L1 and L3. The involvement of these protein regions
in UDG recognition was shown by the analysis of several
single and multiple mutants of p56, in which acidic
residues clustered at these sites or conserved in p56-like
proteins from other f29-related phages, were replaced by
alanines.
In summary, our results indicate that p56 and Ugi,
display a signiﬁcantly different fold. Indeed, p56 deﬁnes
a novel dimeric structure that binds to UDG in a 2:1 stoi-
chiometry. It has been shown that Ugi binding to UDG is
accompanied by a remarkable conformational change of
the inhibitor, involving a substantial reorientation of two
helical segments. Interestingly, the NMR analysis of Ugi
in the free state has revealed that both helices project away
from the b-sheet core, and therefore are located on poten-
tially ﬂexible arms of the polypeptide. This speciﬁc
property would greatly reduce the energy cost of the
observed adjustment. In contrast with Ugi, p56 exhibits
a more compact structure. Indeed, all the secondary struc-
ture elements participate in tight packing interactions,
which seem essential to preserve the structural integrity
of the inhibitor. Consequently, it is highly unlikely that
major structural rearrangements (as those described for
Ugi) take place upon binding to UDG. Nevertheless,
minor adjustments of the protein ﬂexible regions
Figure 5. Inﬂuence of acidic residues on the p56 inhibition activity. The inhibition ability of two triple mutants (D5A/D8A/D11A and D18A/D19A/
D20A) and two single mutants, E26A(A) and E37A(B) of p56 was assayed. Different doses of the mutant proteins (from 0.2 to 18.8ng for the triple
mutants and the E26A mutant and from 0.25 to 16ng for the E37A mutant) were incubated with 5pg of UDG. Then, the DNA substrate was added
and incubated for 20min at 37 C and the product was analysed in 8M urea-20% polyacrylamide gels. (C) After quantiﬁcation by densitometry, the
percentage of inhibition for the mutants was calculated with respect to the wild-type protein. Data are depicted in a bar chart and average values of
three independent experiments with standard deviations are represented.
9786 Nucleic Acids Research, 2011,Vol.39, No. 22(in particular loops L1 and L3 and the N-terminal tail)
would be certainly feasible, and might contribute to
increase the charge and shape complementarity between
enzyme and inhibitor.
Despite the structural differences existing between p56
and Ugi, several ﬁndings suggest that both proteins
present similar inhibition modes. Previous studies
showed that Ugi is able to replace protein p56 previously
bound to E. coli UDG (25), and that UDG position 191 is
required for the inhibition mediated by both inhibitors
(21,30). Furthermore, the present article conﬁrms the
role of acidic residues of p56 in the UDG inhibition, as
previously reported for the formation of UDG–Ugi
complex (15). Thus, these observations suggest that
protein p56 might function as a structural mimic of the
DNA substrate recognized by UDG.
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